과제정보
연구 과제 주관 기관 : Meditox Inc.
참고문헌
- Schwab VD, Sulk M, Seeliger S, Nowak P, Aubert J, Mess C, et al. Neurovascular and neuroimmune aspects in the pathophysiology of rosacea. J Investig Dermatol Symp Proc 2011; 15:53-62. https://doi.org/10.1038/jidsymp.2011.6
- Dayan SH, Pritzker RN, Arkins JP. A new treatment regimen for rosacea: onabotulinumtoxinA. J Drugs Dermatol 2012; 11: e76-e79.
- Bloom BS, Payongayong L, Mourin A, Goldberg DJ. Impact of intradermal abobotulinumtoxinA on facial erythema of rosacea. Dermatol Surg 2015;41 Suppl 1:S9-S16. https://doi.org/10.1097/DSS.0000000000000277
- Shah AR. Use of intradermal botulinum toxin to reduce sebum production and facial pore size. J Drugs Dermatol 2008; 7:847-850.
- Oh YJ, Lee NY, Suh DH, Koh JS, Lee SJ, Shin MK. A split-face study using botulinum toxin type B to decrease facial erythema index. J Cosmet Laser Ther 2011;13:243-248. https://doi.org/10.3109/14764172.2011.613479
- Welch MJ, Purkiss JR, Foster KA. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon 2000;38:245-258. https://doi.org/10.1016/S0041-0101(99)00153-1
- Durham PL, Cady R, Cady R. Regulation of calcitonin generelated peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache 2004;44:35-42. https://doi.org/10.1111/j.1526-4610.2004.04007.x
- Apostolidis A, Popat R, Yiangou Y, Cockayne D, Ford AP, Davis JB, et al. Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol 2005;174:977-982. https://doi.org/10.1097/01.ju.0000169481.42259.54
- Gessert CE, Bamford JT. Measuring the severity of rosacea: a review. Int J Dermatol 2003;42:444-448. https://doi.org/10.1046/j.1365-4362.2003.01780.x
- Park KY, Hyun MY, Jeong SY, Kim BJ, Kim MN, Hong CK. Botulinum toxin for the treatment of refractory erythema and flushing of rosacea. Dermatology 2015;230:299-301. https://doi.org/10.1159/000368773
- Kellogg DL Jr, Pergola PE, Piest KL, Kosiba WA, Crandall CG, Grossmann M, et al. Cutaneous active vasodilation in humans is mediated by cholinergic nerve cotransmission. Circ Res 1995;77:1222-1228. https://doi.org/10.1161/01.RES.77.6.1222
- Kellogg DL Jr, Zhao JL, Wu Y, Johnson JM. Nitric oxide and receptors for VIP and PACAP in cutaneous active vasodilation during heat stress in humans. J Appl Physiol (1985) 2012; 113:1512-1518. https://doi.org/10.1152/japplphysiol.00859.2012
- Steinhoff M, Schauber J, Leyden JJ. New insights into rosacea pathophysiology: a review of recent findings. J Am Acad Dermatol 2013;69(6 Suppl 1):S15-S26. https://doi.org/10.1016/j.jaad.2013.04.045
- Steinhoff M, Buddenkotte J, Aubert J, Sulk M, Novak P, Schwab VD, et al. Clinical, cellular, and molecular aspects in the pathophysiology of rosacea. J Investig Dermatol Symp Proc 2011;15:2-11. https://doi.org/10.1038/jidsymp.2011.7
- Drummond PD, Su D. Endothelial and axon reflex vasodilatation to acetylcholine in rosacea-affected skin. Arch Dermatol Res 2012;304:133-137. https://doi.org/10.1007/s00403-011-1177-1
- Kramer HH, Angerer C, Erbguth F, Schmelz M, Birklein F. Botulinum toxin A reduces neurogenic flare but has almost no effect on pain and hyperalgesia in human skin. J Neurol 2003;250:188-193. https://doi.org/10.1007/s00415-003-0971-x
- Tugnoli V, Capone JG, Eleopra R, Quatrale R, Sensi M, Gastaldo E, et al. Botulinum toxin type A reduces capsaicinevoked pain and neurogenic vasodilatation in human skin. Pain 2007;130:76-83. https://doi.org/10.1016/j.pain.2006.10.030
- Seeliger S, Buddenkotte J, Schmidt-Choudhury A, Rosignoli C, Shpacovitch V, von Arnim U, et al. Pituitary adenylate cyclase activating polypeptide: an important vascular regulator in human skin in vivo. Am J Pathol 2010;177:2563-2575. https://doi.org/10.2353/ajpath.2010.090941
- Goswami C, Rademacher N, Smalla KH, Kalscheuer V, Ropers HH, Gundelfinger ED, et al. TRPV1 acts as a synaptic protein and regulates vesicle recycling. J Cell Sci 2010;123:2045-2057. https://doi.org/10.1242/jcs.065144
- Sulk M, Seeliger S, Aubert J, Schwab VD, Cevikbas F, Rivier M, et al. Distribution and expression of non-neuronal transient receptor potential (TRPV) ion channels in rosacea. J Invest Dermatol 2012;132:1253-1262. https://doi.org/10.1038/jid.2011.424
- Wang TT, Nestel FP, Bourdeau V, Nagai Y, Wang Q, Liao J, et al. Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J Immunol 2004;173:2909-2912. https://doi.org/10.4049/jimmunol.173.5.2909
- Meng J, Ovsepian SV, Wang J, Pickering M, Sasse A, Aoki KR, et al. Activation of TRPV1 mediates calcitonin generelated peptide release, which excites trigeminal sensory neurons and is attenuated by a retargeted botulinum toxin with anti-nociceptive potential. J Neurosci 2009;29:4981-4992. https://doi.org/10.1523/JNEUROSCI.5490-08.2009
- Shimizu T, Shibata M, Toriumi H, Iwashita T, Funakubo M, Sato H, et al. Reduction of TRPV1 expression in the trigeminal system by botulinum neurotoxin type-A. Neurobiol Dis 2012;48:367-378. https://doi.org/10.1016/j.nbd.2012.07.010
- Li X, Coffield JA. Structural and functional interactions between transient receptor potential vanilloid subfamily 1 and botulinum neurotoxin serotype A. PLos One 2016;11:e0143024. https://doi.org/10.1371/journal.pone.0143024
- Eshghi G, Khezrian L, Alirezaei P. Botulinum toxin A in treatment of facial flushing. Acta Med Iran 2016;54:454-457.
피인용 문헌
- Rosacea treatments: Current standards and additional options vol.2, pp.6, 2018, https://doi.org/10.1002/der2.88